Digital Pathology Market worth US$2.75 billion by 2030 with 13.5% CAGR | MarketsandMarkets™
DELRAY BEACH, Fla., June 3, 2025 /PRNewswire/ -- The global Digital Pathology Market, valued at US$1.29 billion in 2024 stood at US$1.46 billion in 2025 and is projected to advance at a resilient CAGR of 13.5% from 2025 to 2030, culminating in a forecasted valuation of US$2.75 billion by the end of the period. The key driver of this growth is the mounting need for telepathology to enable pathologists to remotely view slides and interact live over distances. The other factor is integrating artificial intelligence (AI) in digital pathology systems, boosting diagnostics through automated image analysis and predictive analytics.
Collaborations have compelled the market, which is one of the key factors in play. In March 2024, Amazon Web Services (AWS) (US) and Koninklijke Philips (Netherlands) collaborated to provide cloud-based digital pathology solutions. The intent behind the collaboration was to enhance care delivery by boosting workflow efficiency, improving data security, and facilitating smooth integration with existing healthcare IT infrastructure.
As digital pathology becomes more widely adopted, healthcare organizations are increasingly drawing insights from early implementers to guide their own strategies. However, the market still faces challenges such as a shortage of trained pathologists, high initial investment requirements, and uncertainty around reimbursement policies, which may hinder widespread deployment in some regions.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=844
Browse in-depth TOC on "Digital Pathology Market"
400 - Tables
400 - Figures
350 - Pages
By type, the human pathology segment is expected to experience the fastest growth rate by type throughout the forecast period. The market segmentation of veterinary and human pathology will remain relatively unchanged. Indeed, the human pathology segment is growing rapidly due to the increasing desire for accurate, fast, and effective diagnostic methods. The obvious need for accurate pathology assessments to support treatment planning is becoming progressively highlighted by the rise of chronic diseases such as cancer. Compared to traditional methods, digital pathology enables sophisticated analysis of images, utilizes less physical storage space, offers more efficient slide retrieval, and simplified image collaboration and sharing to obtain second opinions.
By end user, the pharmaceutical & biotechnology companies segment dominated the market in 2024 due to growing drug research, discovery, and personalized medicine use of digital pathology. Digital pathology technology enables companies to use high-resolution images and automated analysis. This speeds up screening, improves the evaluation of tissue samples, identifies drug candidates, and enables high-throughput screening.
By geography, North America led the global digital pathology market in 2024. Its robust investment in health technologies, high rate of chronic disease instances such as cancer, particularly in the US, and developed health infrastructure support this leadership position. Additionally, the region's concentration of key research institutes and companies fosters sustained innovation and the use of digital pathology solutions.
Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=844
Prominent players in the digital pathology market include Huron Digital Pathology (Canada), Hologic, Inc. (US), Corista (US), Indica Labs Inc. (US), 3DHISTECH (Hungary), Objective Pathology Services Limited (Canada), OptraSCAN (US), Sectra AB (Sweden), Akoya Biosciences, Inc. (US), Hamamatsu Photonics K.K. (Japan), F. Hoffmann-La Roche Ltd. (Switzerland), Apollo Enterprise Imaging (US), XIFIN, Inc. (US), Proscia Inc. (US), KONFOONG BIOTECH INTERNATIONAL CO., LTD. (China), Glencoe Software, Inc. (US), Aiforia (Finland), Paige AI, Inc. (US), Fujifilm Holdings Corporation (Japan), Danaher Corporation (US), Koninklijke Philips N.V. (Netherlands), Mikroscan Technologies, Inc. (US), PathAI (US), Motic Digital Pathology (US), and Kanteron Systems (Spain).
Danaher Corporation (US):
Danaher Corporation has emerged as a digital pathology market leader. Leica Biosystems, a subsidiary, provides services ranging from biopsy to radiology, pathology, surgery, and cancer diagnosis. In March 2023, the company partnered with Paige (US) to improve the use of digital pathology workflows in hospitals and laboratories. The cooperation will result in a new diagnostic platform and the co-development of next-generation AI-powered companion diagnostics.
In addition, the company has collaborated with the European Society for Digital and Integrative Pathology (ESDIP) to promote the use of digital pathology throughout Europe. Such initiatives have played a pivotal role in solidifying its leadership in the digital pathology market.
Koninklijke Philips N.V. (Netherlands)
Philips has positioned itself as a market leader in digital pathology by offering solutions that enhance efficiency, cooperation, and diagnostic accuracy. Transitioning from analog to digital workflows enables efficiency gains of 15–20% per case, allowing pathologists to handle more cases in less time. The digitization of workflows supports remote collaboration and faster consensus-building. Philips also addresses the shortage of qualified pathologists by offering tools that streamline workflows and foster multidisciplinary teamwork. Its platform enables real-time consultations and discussions, enhancing patient care. The company has refined its solution based on insights from over 300 customers and 20+ hospital labs.
For more information, Inquire Now!
Related Reports:
Computer Vision in Healthcare Market
Get access to the latest updates on Digital Pathology Companies and Digital Pathology Market Size
About MarketsandMarkets™:
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
Logo: https://mma.prnewswire.com/media/1868219/MarketsandMarkets_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/digital-pathology-market-worth-us2-75-billion-by-2030-with-13-5-cagr--marketsandmarkets-302471498.html
SOURCE MarketsandMarkets